alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1545 Nitrous oxide. ( a ) Nitrous oxide (empirical formula N2O, CAS Reg. No. 10024-97-2) is also known as dinitrogen monoxide or laughing gas. It is a colorless gas, about 50 percent heavier than air, with a slightly sweet smell. It does not burn but will support combustion. Nitrous oxide is manufactured by the thermal decomposition of ammonium nitrate. Higher oxides of nitrogen are removed by passing the dry gas through a series of scrubbing towers.
( b ) The ingredient must be of a purity suitable for its intended use.
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitations other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a propellant, aerating agent, and gas as defined in § 170.3(o)(25) of this chapter.
( 2 ) The ingredient is used in dairy product analogs as defined in § 170.3(n)(10) of this chapter at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 57270, Dec. 29, 1983, as amended at 73 FR 8607, Feb. 14, 2008]
§ 507.53 Requirements applicable to a preventive controls qualified individual and a qualified auditor. ( a ) One or more preventive controls qualified individuals must do or oversee the following: ( 1 ) Preparation of the food safety plan (§ 507.31(b));
( 2 ) Validation of the preventive controls (§ 507.47(b)(1));
( 3 ) Written justification for validation to be performed in a timeframe that exceeds the first 90 calendar days of production of the applicable animal food;
( 4 ) Determination that validation is not required (§ 507.47(c)(4));
( 5 ) Review of records (§ 507.49(a)(4));
( 6 ) Written justification for review of records of monitoring and corrective actions within a timeframe that exceeds 7-working days;
( 7 ) Reanalysis of the food safety plan (§ 507.50(d)); and
( 8 ) Determination that reanalysis can be completed, and additional preventive controls validated, as appropriate to the nature of the preventive control and its role in the facility's food safety system, in a timeframe that exceeds the first 90 calendar days of production of the applicable animal food.
( b ) A qualified auditor must conduct an onsite audit (§ 507.135(a)).
( c ) ( 1 ) To be a preventive controls qualified individual, the individual must have successfully completed training in the development and application of risk-based preventive controls at least equivalent to that received under a standardized curriculum recognized as adequate by FDA or be otherwise qualified through job experience to develop and apply a food safety system. Job experience may qualify an individual to perform these functions if such experience has provided an individual with knowledge at least equivalent to that provided through the standardized curriculum. This individual may be, but is not required to be, an employee of the facility; and
( 2 ) To be a qualified auditor, a qualified individual must have technical expertise obtained through education, training, or experience (or a combination thereof) necessary to perform the auditing function.
( d ) All applicable training in the development and application of risk-based preventive controls must be documented in records, including the date of the training, the type of training, and the person(s) trained.
<TABLE> <S> <C>


<ARTICLE>                     5
<CIK>                         0000813621
<NAME>                        AMCOL International Corporation
<MULTIPLIER>                                   1,000
<CURRENCY>                                     USD

<S>                             <C>
<PERIOD-TYPE>                                  3-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JAN-1-2000
<PERIOD-END>                                   MAR-31-2000
<EXCHANGE-RATE>                                1.00
<CASH>                                         5,467
<SECURITIES>                                   0
<RECEIVABLES>                                  103,195
<ALLOWANCES>                                   4,499
<INVENTORY>                                    47,506
<CURRENT-ASSETS>                               165,832
<PP&E>                                         353,106
<DEPRECIATION>                                 184,225
<TOTAL-ASSETS>                                 347,771
<CURRENT-LIABILITIES>                          56,087
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       320
<OTHER-SE>                                     0
<TOTAL-LIABILITY-AND-EQUITY>                   347,711
<SALES>                                        119,020
<TOTAL-REVENUES>                               119,020
<CGS>                                          91,639
<TOTAL-COSTS>                                  108,771
<OTHER-EXPENSES>                               77
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             1,180
<INCOME-PRETAX>                                8,992
<INCOME-TAX>                                   3,385
<INCOME-CONTINUING>                            5,737
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   5,737
<EPS-BASIC>                                    .21
<EPS-DILUTED>                                  .21


</TABLE>
# L_2020397DE.01003401.xml

| 26.11.2020 | DE | Amtsblatt der Europäischen Union | L 397/34 |
| --- | --- | --- | --- |

26.11.2020

DE

Amtsblatt der Europäischen Union

L 397/34

---

Berichtigung der Delegierten Verordnung (EU) 2018/1063 der Kommission vom 16. Mai 2018 zur Änderung und Berichtigung der Delegierten Verordnung (EU) 2015/2446 zur Ergänzung der Verordnung (EU) Nr. 952/2013 des Europäischen Parlaments und des Rates mit Einzelheiten zur Präzisierung von Bestimmungen des Zollkodex der Union

(
  Amtsblatt der Europäischen Union L 192 vom 30. Juli 2018
  )

Seite 11, Artikel 2 Nummer 1 zur Berichtigung der Überschrift von Artikel 124a der Verordnung (EU) 2015/2446:

Anstatt:

| „(1) | Die Überschrift des Artikels 124a erhält folgende Fassung:

  ‚Artikel 124a
  Nachweis des zollrechtlichen Status von Unionswaren mithilfe eines Versandpapiers ‚T2L‘ oder ‚T2LF‘
  (Artikel 6 Absatz 2, Artikel 6 Absatz 3 Buchstabe a und Artikel 153 Absatz 2 des Zollkodex)‘“ |
| --- | --- |

„(1)

‚Artikel 124a

Nachweis des zollrechtlichen Status von Unionswaren mithilfe eines Versandpapiers ‚T2L‘ oder ‚T2LF‘

(Artikel 6 Absatz 2, Artikel 6 Absatz 3 Buchstabe a und Artikel 153 Absatz 2 des Zollkodex)‘“

muss es heißen:

| „(1) | Die Überschrift des Artikels 124a erhält folgende Fassung:

  ‚Artikel 124a
  Nachweis des zollrechtlichen Status von Unionswaren mithilfe eines Dokuments ‚T2L‘ oder ‚T2LF‘
  (Artikel 6 Absatz 2, Artikel 6 Absatz 3 Buchstabe a und Artikel 153 Absatz 2 des Zollkodex)‘“ |
| --- | --- |

„(1)

‚Artikel 124a

Nachweis des zollrechtlichen Status von Unionswaren mithilfe eines Dokuments ‚T2L‘ oder ‚T2LF‘

(Artikel 6 Absatz 2, Artikel 6 Absatz 3 Buchstabe a und Artikel 153 Absatz 2 des Zollkodex)‘“

Seite 11 des ABl. L 192 vom 30.7.2018, Artikel 2 Nummer 3 zur Berichtigung der Überschrift von Artikel 129a der Verordnung (EU) 2015/2446, in ihrer durch das Korrigendum zur Delegierten Verordnung (EU) 2016/341 (ABl. L 96 vom 5.4.2019, S. 58) berichtigten Form:

Anstatt:

| „(3) | Die Überschrift des Artikels 128a erhält folgende Fassung:

  ‚Artikel 128a
  Förmlichkeiten bei der Ausstellung eines Versandpapiers ‚T2L‘ oder ‚T2LF‘, einer Rechnung oder eines Beförderungspapiers durch einen zugelassenen Aussteller
  (Artikel 6 Absatz 2 und Artikel 6 Absatz 3 Buchstabe a des Zollkodex)‘“ |
| --- | --- |

„(3)

‚Artikel 128a

Förmlichkeiten bei der Ausstellung eines Versandpapiers ‚T2L‘ oder ‚T2LF‘, einer Rechnung oder eines Beförderungspapiers durch einen zugelassenen Aussteller

(Artikel 6 Absatz 2 und Artikel 6 Absatz 3 Buchstabe a des Zollkodex)‘“

muss es heißen:

| „(3) | Die Überschrift des Artikels 128a erhält folgende Fassung:

  ‚Artikel 128a
  Förmlichkeiten bei der Ausstellung eines Dokuments ‚T2L‘ oder ‚T2LF‘, einer Rechnung oder eines Beförderungspapiers durch einen zugelassenen Aussteller
  (Artikel 6 Absatz 2 und Artikel 6 Absatz 3 Buchstabe a des Zollkodex)‘“ |
| --- | --- |

„(3)

‚Artikel 128a

Förmlichkeiten bei der Ausstellung eines Dokuments ‚T2L‘ oder ‚T2LF‘, einer Rechnung oder eines Beförderungspapiers durch einen zugelassenen Aussteller

(Artikel 6 Absatz 2 und Artikel 6 Absatz 3 Buchstabe a des Zollkodex)‘“

---
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.48 Dispute resolution. ( a ) *General.* The Food and Drug Administration is committed to resolving differences between sponsors and FDA reviewing divisions with respect to requirements for IND's as quickly and amicably as possible through the cooperative exchange of information and views.
( b ) *Administrative and procedural issues.* When administrative or procedural disputes arise, the sponsor should first attempt to resolve the matter with the division in FDA's Center for Drug Evaluation and Research or Center for Biologics Evaluation and Research which is responsible for review of the IND, beginning with the consumer safety officer assigned to the application. If the dispute is not resolved, the sponsor may raise the matter with the person designated as ombudsman, whose function shall be to investigate what has happened and to facilitate a timely and equitable resolution. Appropriate issues to raise with the ombudsman include resolving difficulties in scheduling meetings and obtaining timely replies to inquiries. Further details on this procedure are contained in FDA Staff Manual Guide 4820.7 that is publicly available under FDA's public information regulations in part 20.
( c ) *Scientific and medical disputes.* ( 1 ) When scientific or medical disputes arise during the drug investigation process, sponsors should discuss the matter directly with the responsible reviewing officials. If necessary, sponsors may request a meeting with the appropriate reviewing officials and management representatives in order to seek a resolution. Requests for such meetings shall be directed to the director of the division in FDA's Center for Drug Evaluation and Research or Center for Biologics Evaluation and Research which is responsible for review of the IND. FDA will make every attempt to grant requests for meetings that involve important issues and that can be scheduled at mutually convenient times.
( 2 ) The “end-of-Phase 2” and “pre-NDA” meetings described in § 312.47(b) will also provide a timely forum for discussing and resolving scientific and medical issues on which the sponsor disagrees with the agency.
( 3 ) In requesting a meeting designed to resolve a scientific or medical dispute, applicants may suggest that FDA seek the advice of outside experts, in which case FDA may, in its discretion, invite to the meeting one or more of its advisory committee members or other consultants, as designated by the agency. Applicants may rely on, and may bring to any meeting, their own consultants. For major scientific and medical policy issues not resolved by informal meetings, FDA may refer the matter to one of its standing advisory committees for its consideration and recommendations.
[52 FR 8831, Mar. 19, 1987, as amended at 55 FR 11580, Mar. 29, 1990]
<TABLE> <S> <C>

<ARTICLE>                          5
<CIK>                              0000812818
<NAME>                             Hutton Investors Futures Fund, L.P. II

<S>                                  <C>
<PERIOD-TYPE>                      9-MOS
<FISCAL-YEAR-END>                  DEC-31-2000
<PERIOD-START>                     JAN-01-2000
<PERIOD-END>                       SEP-30-2000
<CASH>                               14,678,443
<SECURITIES>                           (956,195)
<RECEIVABLES>                            74,065
<ALLOWANCES>                                  0
<INVENTORY>                                   0
<CURRENT-ASSETS>                     13,796,313
<PP&E>                                        0
<DEPRECIATION>                                0
<TOTAL-ASSETS>                       13,796,313
<CURRENT-LIABILITIES>                 1,655,015
<BONDS>                                       0
<PREFERRED-MANDATORY>                         0
<PREFERRED>                                   0
<COMMON>                                      0
<OTHER-SE>                           12,141,298
<TOTAL-LIABILITY-AND-EQUITY>         13,796,313
<SALES>                                       0
<TOTAL-REVENUES>                     (3,467,083)
<CGS>                                         0
<TOTAL-COSTS>                                 0
<OTHER-EXPENSES>                         26,332
<LOSS-PROVISION>                              0
<INTEREST-EXPENSE>                            0
<INCOME-PRETAX>                      (3,493,415)
<INCOME-TAX>                                  0
<INCOME-CONTINUING>                           0
<DISCONTINUED>                                0
<EXTRAORDINARY>                               0
<CHANGES>                                     0
<NET-INCOME>                         (3,493,415)
<EPS-BASIC>                         (1,065.97)
<EPS-DILUTED>                                 0


</TABLE>
§ 225.115 Complaint files. ( a ) Complaints and reports of experiences of product defects relative to the drug's efficacy or safety may provide an indicator as to whether or not medicated feeds have been manufactured in conformity with current good manufacturing practices. These complaints and experiences may reveal the existence of manufacturing problems not otherwise detected through the normal quality control procedures. Timely and appropriate follow-up action can serve to correct a problem and minimize future problems.
( b ) The medicated feed manufacturer shall maintain on the premises a file which contains the following information: ( 1 ) The original or copy of a record of each oral and written complaint received relating to the safety and effectiveness of the product produced. The record shall include the date of the complaint, the complainant's name and address, name and lot or control number or date of manufacture of the medicated feed involved, and the specific details of the complaint. This record shall also include all correspondence from the complainant and/or memoranda of conversations with the complainant, and a description of all investigations made by the manufacturer and of the method of disposition of the complaint.
( 2 ) For medicated feeds whose manufacture require a medicated feed mill license (Form FDA 3448), records and reports of clinical and other experience with the drug shall be maintained and reported, under § 510.301 of this chapter.
[41 FR 52618, Nov. 30, 1976, as amended at 51 FR 7390, Mar. 3, 1986; 57 FR 6475, Feb. 25, 1992; 64 FR 63203, Nov. 19, 1999]
Exhibit 15.2




[BDO Auditores S.L.P. Letterhead]




CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM




We hereby consent to the incorporation by reference in the Registration Statements on Forms S-8 (File Nos. 333-187533, 333-102288 and 333-92491) pertaining to the Employee Stock Option plans of Ellomay Capital Ltd. (the “Company”) and Forms F-3 (File Nos. 333-199696 and 333-144171) of the Company of our report dated April 29, 2015 with respect to the 2014 consolidated financial statements of Ellomay Spain, S.L. included in the Annual Report on Form 20-F of the Company for the year ended December 31, 2015.




/s/ BDO Auditores S.L.P.


BDO Auditores S.L.P.





Spanish Certified Public Accountants





Madrid, Spain


March 21, 2016
Exhibit 32.02

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of Amerityre Corporation (the "Company") on Form 10-
QSB for the quarter ended June 30, 2005, as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), I, Anders A. Suarez,
Chief Financial Officer [Principal Financial Officer], of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and
belief:

 (1) the Report fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and

 (2) the information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company.


/S/ Anders A. Suarez
Anders A. Suarez
Chief Financial Officer

September 16, 2005

A signed original of this written statement required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature
that appears in typed form within the electronic version of this written
statement has been provided to the Company and will be retained by the Company
and furnished to the Securities and Exchange Commission or its staff upon
request.
§ 182.8997 Zinc sulfate. ( a ) *Product.* Zinc sulfate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing practice.
```

                        CERTIFICATION OF CFO PURSUANT TO
                 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of M & F Worldwide Corp. (the
"Company") for the period ended December 31, 2005 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Todd J. Slotkin,
as Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that, to the best of my knowledge:

     (1) The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

     (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

        /s/ Todd J. Slotkin
--------------------------------
Name:   Todd J. Slotkin
Title:  Chief Financial Officer
Date:   March 15, 2006
```
#### Longenbach v. Longenbach

*Henry Villa,*for plaintiff.

*Robert Ritter,*for defendant.

March 12, 1951.

Henninger, P. J.,

— Plaintiff in-instituted the above action in divorce on October 5, 1949. On November 17, 1949, the date set for a hear*444ing, defendant appeared personally and requested the opportunity to procure counsel, whereupon the master set December 2,1949, as the date for hearing. On that date, defendant and her counsel appeared and called the master’s attention to the fact that a rule was pending for counsel fees and the hearing was postponed to a date to be agreed upon.

After several futile efforts to get the parties to determine the rule for counsel fees, the master, in December 1950, notified plaintiff’s counsel that unless the case was proceeded with prior to February 1, 1951, he would file a report recommending dismissal of the libel. This warning having produced no results, the master has filed a report recommending dismissal of the libel for failure to prosecute the same.

For a plaintiff in divorce to establish his case, he must come forward with satisfactory evidence: Esenwein v. Esenwein, 312 Pa. 77, 78. This plaintiff has not done, although challenged to do so on several occasions. That he was barred from.doing so by the stay accompanying his wife’s rule for counsel fees is no excuse, since he could have forced that issue had he seen fit to do so. Clearly then, the master was within his rights •in compelling the parties to proceed and upon their failure to heed his importunities, to recommend dismissal of the libel, since the burden was on plaintiff to establish his case: Esenwein v. Esenwein, supra; Waring et al. v. The Pennsylvania Railroad Company, 176 Pa. 172, 176. Both parties have received notice of the filing of the master’s report recommending dismissal of the libel and neither one has excepted thereto.

Now, March 12, 1951, the report of the master and examiner is confirmed and his recommendation adopted by the court and it is ordered and decreed that the libel be dismissed at plaintiff’s costs.
AUG-05-2013 13:05 

### DOMBROFF GILMORE

AIMI'ly Atlanta Brussels Denver Los Anggles Mieml New York 

# McKenna Long &:

# AldridgeLL,. 111 Washington Avenue • 71h Floor Albany, NY 12210 Tel: 518.935.2400 • Fax: 518.462.4875 mckennalong.com


## FACSIMILE TRANSMITTAL

To:

From: Phone: Re: Name/Company The Honorable Ronnie A. 

## Yoder U.S 

## Department ofTransportation Mark A. Dombroff 703.336.8700 Colgan Air, Inc. Fax No. (202) 493-5142

FAA Docket No. CP09EA0002, -0005, -0016 Number ofPages (including cover): 

# .!J:::. COMMENTS

Confidentiality Notice 7033358751 P.01
Northem Vlrglnia**O~nge** COUI'Ity**R:~l'lcho** Santa Fe Sen OlegD**S~n** Francisco Seoul WeshlnglOn, oC



## Date: August 5, 2013 Phone No. (202) 366-2142

The information contained in this facsimile is legally privileged and confidential information intended only for the use ofthe individual or entity named above. lfthe reader ofthis message is not the intended recipient, you are hereby notified that any dissemination, distribution or copy ofthis telecopy is mictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone and return the original message to us at the address abovo. Thankyou. 

### If

### transmission is unclear or incomplete, please call sender at the above phone number.AUG-05-2013 13'06 DOMBROFF GILMORE 7033368751 P.02 Albany Atlanta Brusscl$ De!'lver LOS Angeles Miami New York 

# McKenna Long &

# AldridgeLLP**16:1'6lnt~trnational** Drive • Penthouse Mclean, VA 221 02 Tok 703.336.8800**rnckennalong.~;om** Northt:tn Vlrginla Orangl!: County Rancho Santa Fe**S~n** Diego

$;;tn**Fri!lnd~o** Wa.$hing(on, DC

MARK A. DOMBROFF 703.336.6700 EMAIL ADDRESS mdombmff@mckennalong.com 

### August 5, 2013

VIA FACSIMILE AND FIRST CLASS MAIL 

### The Honorable Ronnie A. Yoder ChiefAdministrative Law Judge U.S Department ofTransportation Office ofHearings, M-20 Room E12-320 1200 New Jersey Avenue, S.E. Washington, D.C. 20590 Re: Colgan Air, Inc. FAA Docket No. CP09EA0002, -0005, -0016 Dear Judge Yoder: Our client is agreeable to entry ofthe order submitted to you on July 29, 2013, inthe above-referenced matter. We look forward to achieving a resolution ofthese matters with the Federal Aviation Administration and advising you ofsuch. Thank you for your patience.

MAD cc; Chris Lewereuz

TOTAL P.02